Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 801–900 of 1,007
Khan, K. A., Wu, F. T. H., Cruz‐Muñoz, W., & Kerbel, R. S. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201708253 · Cited by 56
Self-citationInsulin Increases Tristetraprolin and Decreases VEGF Gene Expression in Mouse 3T3–L1 Adipocytes
Cao, H., Urban, J. F., & Anderson, R. A. (2008) · Obesity · doi:10.1038/oby.2008.65 · Cited by 53
Martinelli, M., Bonezzi, K., Riccardi, E., Kuhn, E., Frapolli, R., Zucchetti, M., Ryan, A. J., Taraboletti, G., & Giavazzi, R. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603969 · Cited by 53
“…therapy) or to damage already formed vessels (vascular targeting/disrupting therapy) have been developed and have shown efficacy in preclinical models, and recently, in clinical studies (Taraboletti and Margosio, 2001; Thorpe, 2004; Ferrara and Kerbel, 2005; Tozer et al, 2005; Chaplin et al, 2006).”
BackgroundMolecular imaging of myocardial infarction
Jaffer, F. A., Sosnovik, D. E., Nahrendorf, M., & Weissleder, R. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.09.008 · Cited by 56
Oguro, Y., Cary, D. R., Miyamoto, N., Tawada, M., Iwata, H., Miki, H., Hori, A., & Imamura, S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.042 · Cited by 53
Angiogenesis: An update and potential drug approaches (Review)
Abdelrahim (2009) · International Journal of Oncology · doi:10.3892/ijo_00000470 · Cited by 59
Wlodarczyk, L., Szelenberger, R., Cichon, N., Saluk-Bijak, J., Bijak, M., & Miller, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083949 · Cited by 51
“The second receptor, may induce the stimulation of matrix metalloproteinases (MMPs) and the release of endothelial growth factors [24].”
BackgroundDevelopment of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Keane, P. A., & Sadda, S. R. (2012) · Journal of Ophthalmology · doi:10.1155/2012/483034 · Cited by 51
“Thus, despite the complexity of the angiogenic process, and the potential redundancy of the growth factors involved, VEGF blockade was quickly recognized as a promising approach for the restriction of blood vessel formation in a variety of pathologic scenarios [8].”
BackgroundGangjee, A., Zaware, N., Raghavan, S., Ihnat, M. A., Shenoy, S. S., & Kisliuk, R. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9011142 · Cited by 52
Zisa, D., Shabbir, A., Mastri, M., Suzuki, G., & Lee, T. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00227.2009 · Cited by 51
Li, J., & Li, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3040 · Cited by 53
“Angiogenesis is required by many solid tumors to grow beyond a certain size (5, 6) and is closely related to metastasis of solid tumors, including melanoma (7–9).”
BackgroundHu, Z., Brooks, S. A., Dormoy, V., Hsu, C.-W., Hsu, H.-Y., Lin, L., Massfelder, T., Rathmell, W. K., Xia, M., Al‐Mulla, F., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv036 · Cited by 56
MiR‐150 Regulates Poststroke Cerebral Angiogenesis via Vascular Endothelial Growth Factor in Rats
He, Q., Li, Q., Jin, H., Fang, Z. H., Baral, S., Zhu, Y., Xia, Y., Mao, L., Chen, X., & Hu, B. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12525 · Cited by 51
“Induction of angiogenesis is one of the most promising therapeutic strategies for stroke and it helps to restore blood supply after the attack, thereby promoting recovery of brain function [1, 2].”
BackgroundCurrent progress in antivascular tumor therapy
Ho, Y.-J., Wang, T.-C., Fan, C., & Yeh, C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.001 · Cited by 57
Oguido, A. P. M. T., Hohmann, M. S., Pinho-Ribeiro, F. A., Crespigio, J., Domiciano, T. P., Verri, W. A., Jr., & Casella, A. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19702 · Cited by 55
“During neovascularization, several positive and negative regulators control the cascade of events that contributes to angiogenesis.(8) Among them, inflammation plays an important role in pathologic neovascularization in several diseases.”
BackgroundChen, X., Zhang, S., Du, K., Zheng, N., Liu, Y., Chen, H., Xie, G., Ma, Y., Zhou, Y., Zheng, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14740 · Cited by 52
Fabricius, E., Wildner, G. P., Kruse-Boitschenko, U., Hoffmeister, B., Goodman, S. L., & Raguse, J.-D. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.171 · Cited by 55
Identification of alterations in DNA copy number in host stromal cells during tumor progression
Pelham, R. J., Rodgers, L., Hall, I., Lucito, R., Nguyen, K. C. Q., Navin, N., Hicks, J., Mu, D., Powers, S., Wigler, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609635104 · Cited by 52
Semaphoring Vascular Morphogenesis
Bussolino, F., Valdembri, D., Caccavari, F., & Serini, G. (2006) · Endothelium · doi:10.1080/10623320600698003 · Cited by 52
Early Clinical Studies of Novel Therapies for Thyroid Cancers
Sherman, S. I. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.02.005 · Cited by 51
“VEGFR-3 is also a member of the same family as VEGFR-1 and -2; however, it preferentially binds VEGF-C andVEGF-D, and is associated with lymphangiogenesis [11].”
BackgroundHu, B., Gao, J., Lu, Y., & Wang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102370 · Cited by 61
“Indeed, numerous ischemic animal models have shown that VEGF 165 can induce angiogenesis and promote revascularization and recovery [160–162].”
BackgroundAdvances in functional lipid nanoparticles: from drug delivery platforms to clinical applications
Dhayalan, M., Wang, W., Riyaz, S. U. M., Dinesh, R. A., Shanmugam, J., Irudayaraj, S. S., Stalin, A., Giri, J. P., Mallik, S., & Hu, R. (2024) · 3 Biotech · doi:10.1007/s13205-023-03901-8 · Cited by 56
“…blood supply to the tumor, depriving it of the nutrients needed for rapid spread, and blocking a route for metastasis is what drove the development of vascular-targeted nanoparticles as anti-vascular agent routes of administration to tumor-associated endothelial cells (Ferrara and Kerbel 2005).”
InfluentialTargeting angiogenesis in ovarian cancer
Schmitt, J., & Matei, D. E. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.004 · Cited by 57
Norcantharidin inhibits tumor angiogenesis via blocking VEGFR 2/ MEK / ERK signaling pathways
Zhang, L., Ji, Q., Liu, X., Chen, X., Chen, Z., Qiu, Y., Sun, J., Cai, J., Zhu, H., & Li, Q. (2013) · Cancer Science · doi:10.1111/cas.12120 · Cited by 50
Lassen, U., Nielsen, D. L., Mau‐Sørensen, M., Winstedt, L., Niskanen, T., Stenberg, Y., Pakola, S., Stassen, J. M., & Glazer, S. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.609 · Cited by 52
“Angiogenesis (new blood vessel formation) has a critical role in the development and maintenance of cancer and it is widely recognised that tumours must induce angiogenesis to grow beyond a size of 1 –2 mm in diameter, as well as to metastasise to distant organ sites (Carmeliet, 2003; Ferrara and Kerbel, 2005).”
BackgroundAnti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice
Tsujie, M., Tsujie, T., Toi, H., Uneda, S., SHIOZAKI, K., Tsai, H., & Seon, B. K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23314 · Cited by 50
“Angiogenesis is essential for tumor growth, progression and metastasis and antiangiogenic therapy has become a new promising strategy in the treatment of cancer patients.(1,2) Antiangiogenic therapy may have advantages over conventional tumor cell-targeted therapies including chemotherapy and immunotherapy.”
BackgroundIn Vivo Optical Imaging of Tumor and Microvascular Response to Ionizing Radiation
Maeda, A., Leung, M. K. K., Conroy, L., Chen, Y., Bu, J., Lindsay, P. E., Mintzberg, S., Virtanen, C., Tsao, J., Winegarden, N. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042133 · Cited by 56
Li, Y., Duan, C.-L., & Liu, J. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.019 · Cited by 50
Noscapine inhibits tumor growth in TMZ-resistant gliomas
Jhaveri, N., Cho, H., Torres, S., Wang, W., Schönthal, A. H., Petasis, N. A., Louie, S. G., Hofman, F. M., & Chen, T. C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.015 · Cited by 50
“The tumor vasculature is critical for tumor growth [27], and therapeutic targeting of the blood vesselswith different anti-angiogenic agents has been shown to result in tumor shrinkage [28].”
BackgroundSoluble forms of VEGF receptor‐1 and ‐2 promote vascular maturation via mural cell recruitment
Lorquet, S., Berndt, S., Blacher, S., Gengoux, E., Peulen, O., Maquoi, E., Noël, A., Foidart, J., Munaut, C., & Péqueux, C. (2010) · The FASEB Journal · doi:10.1096/fj.09-149070 · Cited by 54
The Future of Targeted Therapies in Ovarian Cancer
Banerjee, S. N., & Gore, M. E. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0013 · Cited by 54
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho, A., Gomes, M. P., Catarino, R., Rolfo, C. D., Lopes, A. M., Medeiros, R., & Araújo, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7794 · Cited by 51
Dharmasivam, M., Kumar, R. S., & Rahiman, A. K. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.085 · Cited by 50
Salt Sensitivity of Angiogenesis Inhibition–Induced Blood Pressure Rise
Lankhorst, S., Severs, D., Markó, L., Rakova, N., Titze, J. M., Müller, D. N., Danser, A. H. J., & van den Meiracker, A. H. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08565 · Cited by 50
Tsakiroglou, P., VandenAkker, N. E., Bo’, C. D., Riso, P., & Klimis‐Zacas, D. J. (2019) · Nutrients · doi:10.3390/nu11051075 · Cited by 55
“A better understanding of molecular pathways involved in angiogenesis is critical [25].”
BackgroundInfluentialLi, Z., Wang, Y., Zhu, J., Zhang, Y., Zhang, W., Zhou, M., Luo, C., Li, Z. J., Cai, B., Gui, S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.007 · Cited by 51
The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function
Urbantat, R. M., Blank, A., Kremenetskaia, I., Vajkoczy, P., Acker, G., & Brandenburg, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052634 · Cited by 56
“The positive effect of VEGF on endothelial cells is well known, while influence by CXCL2 and IL8 is analyzed to a lesser extent [36,37].”
BackgroundSchomber, T., Kopfstein, L., Djonov, V., Albrecht, I., Baeriswyl, V., Strittmatter, K., & Christofori, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1034 · Cited by 52
Pharmacogenetics of EGFR and VEGF inhibition
Pander, J., Gelderblom, H. A. J., & Guchelaar, H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.016 · Cited by 55
Bronte, G., Bronte, E., Novo, G., Pernice, G., Vullo, F. L., Musso, E., Bronte, F., Gulotta, E., Rizzo, S., Rolfo, C. D., et al. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.986092 · Cited by 49
“These anti-angiogenic drugs act on the development of new blood vessels that furnish an adequate metabolic contribution to the microenvironment, which is necessary for tumor growth and its systemic spread [1].”
BackgroundClinical biomarkers of angiogenesis inhibition
Brown, A. P., Citrin, D. E., & Camphausen, K. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9143-x · Cited by 50
Zhang, X., Raghavan, S., Ihnat, M. A., Thorpe, J. E., Disch, B. C., Bastian, A., Bailey‐Downs, L. C., Dybdal‐Hargreaves, N. F., Rohena, C. C., Hamel, E., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.04.049 · Cited by 50
Duong, H. T., ERZURUM, S. C., & Asosingh, K. (2011) · Angiogenesis · doi:10.1007/s10456-011-9228-y · Cited by 57
“In conditions of pathological vascularization, such as tumor proliferation [1, 18] and”
Yang, C., Zhou, Y., Wang, R.-J., & Hu, M. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.03.034 · Cited by 49
Jiang, S., Wang, Y., Yang, J., Li, J., Feng, M., Wang, Y.-H., Zhang, X.-X., He, P., Tian, G.-A., Zhang, X.-X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6772 · Cited by 54
RetractedKurmi, B. D., Patel, P., Paliwal, R., & Paliwal, S. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101682 · Cited by 55
Wang, P., Zhen, H., Zhang, J., Zhang, W., Zhang, R., Cheng, X., Guo, G., Mao, X., Wang, J., & Zhang, X. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20829 · Cited by 52
“migration and elevate MVD in tumors in a paracrine manner [16].”
BackgroundDecrease in VEGF Expression Induces Intussusceptive Vascular Pruning
Hlushchuk, R., Ehrbar, M., Reichmuth, P., Heinimann, N., Styp‐Rekowska, B., Escher, R., Baum, O., Lienemann, P. S., Makanya, A. N., Keshet, E., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.231811 · Cited by 49
Zhang, T., & Sentman, C. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201314 · Cited by 53
Li, S., Dang, Y., Lam, G. O., Kwan, Y. W., Chan, S., Leung, G., Lee, S. M., & Hoi, M. P. M. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.09.005 · Cited by 49
Kıyan, H. T., Demırcı, B., Başer, K. H. C., & Demi̇rci̇, F. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.810647 · Cited by 48
Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
de Jesús-González, N., Robinson, E., Penchev, R., von Mehren, M., Heinrich, M. C., Tap, W. D., Wang, Q., Demetri, G. D., George, S., & Humphreys, B. D. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.97 · Cited by 49
Combination treatment including targeted therapy for advanced hepatocellular carcinoma
Lin, J., Wu, L., Bai, X., Xie, Y., Wang, A., Zhang, H., Yang, X., Wan, X., Lu, X., Sang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11954 · Cited by 48
Sun, W., Hu, S., Fang, S., & Yan, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.04.005 · Cited by 54
Vicente‐Blázquez, A., González, M., Álvarez, R., Mazo, S. D., Medarde, M., & Peláez, R. (2018) · Medicinal Research Reviews · doi:10.1002/med.21541 · Cited by 52
Comparative Analysis of Metastasis Variants Derived from Human Prostate Carcinoma Cells
Conn, E. M., Bøtkjær, K. A., Kupriyanova, T. A., Andreasen, P. A., Deryugina, E. I., & Quigley, J. P. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090384 · Cited by 49
“Moreover, reduced primary tumor size makes it difficult to determine direct effects of anti-angiogenic treatment on tumor metastasis.(41,42) In the CAM model, on the other hand, it appears that the intratumoral angiogenic vessels, remaining after anti-VEGF treatment along with the pre-existing CAM blood vessels, are a…”
BackgroundMulti-scale Computational Models of Pro-angiogenic Treatments in Peripheral Arterial Disease
Gabhann, F. M., Ji, J. W., & Popel, A. S. (2007) · Annals of Biomedical Engineering · doi:10.1007/s10439-007-9303-0 · Cited by 49
Kim, E. H., Na, H., & Surh, Y. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.041 · Cited by 50
Gonçalves, V., Gautier, B., Regazzetti, A., Coric, P., Bouaziz, S., Garbay, C., Vidal, M., & Inguimbert, N. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.087 · Cited by 48
Baicalein Induces Functional Hypoxia-Inducible Factor-1α and Angiogenesis
Cho, H.-J., Lee, H.-Y., Ahn, D., Kim, S.-Y., Kim, S., Lee, K. B., Lee, Y. M., Park, H., & Yang, E. G. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.040162 · Cited by 50
“Because VEGF is a principal endogenous growth factor implicated in early vasculogenesis, its administration by gene or protein therapy has been extensively attempted in therapeutic angiogenesis for the treatment of ischemic disorders (Ferrara and Kerbel, 2005).”
BackgroundSasaki, T., Nakamura, T., Rebhun, R. B., Cheng, H., Stemke‐Hale, K., Tsan, R. Z., Fidler, I. J., & Langley, R. R. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071147 · Cited by 54
Copper in hepatocellular carcinoma: A double-edged sword with therapeutic potentials
Wu, Z., Lv, G., Xing, F., Xiang, W., Ma, Y., Feng, Q., Yang, W. K., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216348 · Cited by 52
Shi, L., Wu, T.-T., Wang, Z., Xue, J., & Xu, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.071 · Cited by 47
Holzer, T. R., Fulford, A. D., Nedderman, D. M., Umberger, T. S., Hozak, R. R., Joshi, A., Melemed, S. A., Benjamin, L. E., Plowman, G. D., Schade, A. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080292 · Cited by 47
Rahbari, N. N., Reißfelder, C., Mühlbayer, M., Weidmann, K., Kahlert, C., Büchler, M. W., Weitz, J., & Koch, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1761-9 · Cited by 47
Pei, J., Zhang, J., Sumariwalla, P. F., Ni, I., Jorgensen, B., Crawford, D., Phillips, S. L., Feldmann, M., Shepard, H. M., & Paleolog, E. M. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2447 · Cited by 53
“Inhibiting angiogenesis is a promising strategy for treatment of neovascularization-related diseases [58], including RA [26].”
BackgroundExpression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
Rahbari, N. N., Schmidt, T., Falk, C. S., Hinz, U., Herber, M., Bork, U., Büchler, M. W., Weitz, J., & Koch, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-286 · Cited by 51
“Furthermore, they may serve as biomarkers to predict the response or resistance to chemotherapy or anti-angiogenic therapy [28,29].”
MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells
Liu, M., Wang, D., & Li, N. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14562725373752 · Cited by 46
Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis
Noh, K., Mangala, L. S., Han, H., Zhang, N., Pradeep, S., Wu, S. Y., Ma, S., Mora, E., Rupaimoole, R., Jiang, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.020 · Cited by 49
“Currently, the most broadly used anti-angiogenesis drug is bevacizumab, a monoclonal antibody that blocks the activity of VEGF-A (Ferrara and Kerbel, 2005).”
BackgroundHuang, C., Wang, T.-C., Lin, B.-H., Wang, Y., Johnson, S. L., & Yu, J. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.06.003 · Cited by 47
“This relationship has inspired the idea of applying antiangiogenesis therapies for cancer, which has already produced encouraging results in both laboratory and clinical settings (Ferrara and Kerbel, 2005).”
Angiogenesis as a strategic target for prostate cancer therapy
Li, Y., & Cozzi, P. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20161 · Cited by 54
“Basic and clinical studies indicate that suppression of angiogenesis can inhibit tumor progression and metastasis.(26) In this review, we summarize the role and regulation of angiogenic factors in CaP progression and the potential therapeutic significance in control of late stage, CRPC disease to overcome the resistan…”
BackgroundBiogenic carbon dot-based fluorescence-mediated immunosensor for the detection of disease biomarker
Deb, A., Nalkar, G. R., & Chowdhury, D. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340808 · Cited by 48
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Batalla, I. B., Cubas‐Cordova, M., Udonta, F., Wroblewski, M., Waizenegger, J. S., Janning, M., Sawall, S., Gensch, V., Zhao, L., Martínez-Zubiaurre, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3437 · Cited by 50
Stroke angiogenesis and phytochemicals
Lin, T.-N. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s287 · Cited by 46
Lyons, J. A., Sheahan, B. J., Galbraith, S. E., Mehra, R., Atkins, G. J., & Fleeton, M. N. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302889 · Cited by 46
Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression
Wu, S., Lin, S., Lee, K., Chuang, H., Feng, P., Cheng, W., Liao, C., Chi, H., Lin, Y.-H., Tsai, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30559 · Cited by 46
“Angiogenesis may be a target for combating diseases characterized by either poor vascularization or abnormal vasculature.(27) Clinical data showed an association of high expression of NEK2 with vascular invasion (Table 1).”
BackgroundWang, Y., Sun, Y., Wang, Y., Ju, Y., & Meng, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102924 · Cited by 47
Medication Trends for Age-Related Macular Degeneration
Cho, Y.-K., Park, D.-H., & Jeon, ⋅.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111837 · Cited by 53
Noël, A., Jost, M., Lambert, V., Lecomte, J., & Rakic, J. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.06.005 · Cited by 53
Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer
Shibuya, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392987 · Cited by 46
Different effects of catechin on angiogenesis and inflammation depending on VEGF levels
Negrão, R., Costa, R., Duarte, D., Taveira‐Gomes, T., Azevedo, I., & Soares, R. A. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.12.011 · Cited by 46
“In the adult, angiogenesis maintains physiological homeostasis and tissue integrity during wound healing, inflammation, endometrial growth in menstrual cycle and following ischemia [3,4].”
BackgroundIyer, S., Scotney, P. D., Nash, A. D., & Acharya, K. R. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.03.002 · Cited by 47
Peng, F.-W., Wu, T.-T., Ren, Z., Xue, J., & Shi, L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.006 · Cited by 48
Fanhchaksai, K., Okada, F., Nagai, N., Pothacharoen, P., Kongtawelert, P., Hatano, S., Makino, S., Nakamura, T., & Watanabe, H. (2015) · International Journal of Cancer · doi:10.1002/ijc.29804 · Cited by 48
Shin, S.-H., Lee, J., Lim, K. S., Rhim, T., Lee, S. K., Kim, Y., & Lee, K. Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.020 · Cited by 45
Collet, G., Skrzypek, K., Grillon, C., Matejuk, A., Hafny‐Rahbi, B. E., Lamerant‐Fayel, N., & Kiéda, C. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.03.001 · Cited by 47
Kim, G. D. (2014) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2014.19.4.299 · Cited by 45
Bruneau, S., Woda, C. B., Daly, K. P., Boneschansker, L., Jain, N. G., Kochupurakkal, N. M., Contreras, A. G., Seto, T., & Briscoe, D. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00054 · Cited by 49
“MICROVASCULAR PATTERNING AND THE INTRAGRAFT MICROENVIRONMENT Angiogenesis, the generation of new blood vessels from preexisting ones, is a complex process involving the degradation of the vascular basement membrane and surrounding extracellular matrix as well as EC proliferation and migration (Cotran, 1994; Folkman, 1…”
BackgroundThe Retinoid Agonist Tazarotene Promotes Angiogenesis and Wound Healing
Zen, A. A. H., Nawrot, D. A., Howarth, A., Caporali, A., Ebner, D. V., Vernet, A., Schneider, J. E., & Bhattacharya, S. (2016) · Molecular Therapy · doi:10.1038/mt.2016.153 · Cited by 46
(−)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway
Gu, Y., Wang, J., & Peng, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5270 · Cited by 48
“Angiogenesis plays a critical role in the growth and metastasis of malignant tumors as the newly formed tumor vasculature serve initially as feeding tubes providing nutrients and oxygen for the tumor mass (31).”
BackgroundInvestigation of the role of nitric oxide driven angiogenesis by zinc oxide nanoflowers
Barui, A. K., Nethi, S. K., & Patra, C. R. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb03323g · Cited by 47
MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
Schanza, L.-M., Seles, M., Stotz, M., Foßelteder, J., Hutterer, G. C., Pichler, M., & Stiegelbauer, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112495 · Cited by 46
“Moreover, the promotion of angiogenesis might be used to treat cardiovascular heart diseases, whereas anti-angiogenesis treatments might provide benefits in various tumor therapies, in particular in RCC [36,37].”
BackgroundChen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance
Wang, X., Zhang, J., Cao, G., Hua, J., Shan, G., & Lin, W. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02432-z · Cited by 47
Antiangiogenic therapy in malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831186ba · Cited by 46
Mechanism of inhibition of tumor angiogenesis by β‐hydroxyisovalerylshikonin
Komi, Y., Suzuki, Y., Shimamura, M., Kajimoto, S., Nakajo, S., Masuda, M., Shibuya, M., Itabe, H., Shimokado, K., Oettgen, P., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01049.x · Cited by 48
Wilkinson, B., Gregory, M. A., Moss, S. J., Carletti, I., Sheridan, R., Kaja, A. L., Ward, M., Olano, C., Méndez, C., Salas, J. A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.073 · Cited by 47
The polyamines regulate endothelial cell survival during hypoxic stress through PI3K/AKT and MCL-1
Kucharzewska, P., Welch, J. E., Svensson, K. J., & Belting, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.097 · Cited by 47
Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
Kerbel, R. S. (2007) · Cancer Research and Treatment · doi:10.4143/crt.2007.39.4.150 · Cited by 45
Self-citationLiang, F., Han, Y., Gao, H., Xin, S., Chen, S., Wang, N., Qin, W., Zhong, H., Lin, S., Yao, X., et al. (2015) · Scientific Reports · doi:10.1038/srep14468 · Cited by 45
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.